Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Unicycive Therapeutics Inc UNCY

Healthcare Biotechnology
Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. Oxylanthanum Carbonate and UNI 494 were initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum) and Sphaera Pharma, respectively.


NDAQ:UNCY - Post by User

Unicycive Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(250)
•••
Post by whytestockson Jun 25, 2024 7:00pm
70 Views
Post# 36106041

Unicycive Therapeutics Achieves Study Objective in Oxylantha

Unicycive Therapeutics Achieves Study Objective in Oxylantha
Just In: $UNCY Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial&#x2013; Successfully Established Favorable Tolerability and Safety of OLC &#x2013; &#x2013; New Drug Application (NDA) Submission Anticipated in Q3 2024 &#x2013; &#x2013; Webcast and Conference Call Today at 8:30 A.M. ET &#x2013; LOS ALTOS, Calif., June 25, 2024 (GLOBE NE...UNCY - Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities